Radiofrequency ablation as a treatment tool for liver metastases of colorectal origin.
TLDR
A possible role of RFA in resectable CRLM is reflected on after multiple attempts to assess the possible contribution of radiofrequency ablation to improve OS and progression-free survival (PFS) in patients with unresectable colorectal liver metastases.Abstract:
At diagnosis 10-25% of patients with colorectal liver metastases (CRLM) present as resectable disease. Liver resection is the gold standard treatment, resulting in a 5-year overall survival (OS) of 22-58%, local recurrence rates of 1.2-10.4% and a perioperative mortality of less than 5%. Multiple attempts have been made to assess the possible contribution of radiofrequency ablation (RFA) to improve OS and progression-free survival (PFS) in patients with unresectable colorectal liver metastases. The aim of this paper is to review the RFA literature in the setting of colorectal liver metastases: RFA with and without chemotherapy, RFA with and without resection, RFA for solitary unresectable CRLM, surgical and percutaneous imaging-guided RFA, RFA compared with chemotherapy. The reported OS, PFS, local recurrence rates, morbidity and mortality in these different settings are analyzed. This paper reflects on a possible role of RFA in resectable CRLM.read more
Citations
More filters
Journal ArticleDOI
Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial
Theo J.M. Ruers,Frits van Coevorden,Cornelis J. A. Punt,Jean-Pierre E. N. Pierie,Inne H. M. Borel-Rinkes,Jonathan A. Ledermann,Graeme J. Poston,Wolf O. Bechstein,M.A. Lentz,Murielle Mauer,Gunnar Folprecht,Eric Van Cutsem,Michel Ducreux,Bernard Nordlinger +13 more
TL;DR: This phase II trial is the first randomized study demonstrating that aggressive local treatment can prolong OS in patients with unresectable colorectal liver metastases.
Journal ArticleDOI
Thermal ablation of colorectal liver metastases: a position paper by an international panel of ablation experts, the interventional oncology sans frontières meeting 2013
Alice Gillams,Nahum Goldberg,Muneeb Ahmed,Reto Bale,David J. Breen,Matthew R. Callstrom,Min-hua Chen,Byung Ihn Choi,Thierry de Baere,Damian E. Dupuy,Afshin Gangi,Debra A. Gervais,Thomas Helmberger,Ernst Michael Jung,Fred T. Lee,Riccardo Lencioni,Ping Liang,Tito Livraghi,David S.K. Lu,Franca Meloni,Philippe L. Pereira,Fabio Piscaglia,Hyunchul Rhim,Riad Salem,Constantinos T. Sofocleous,Stephen B. Solomon,Michael C. Soulen,Masatoshi Tanaka,Thomas J. Vogl,Brad Wood,Luigi Solbiati +30 more
TL;DR: A consensus document making recommendations on the appropriate application of thermal ablation in patients with colorectal liver metastases is provided to facilitate judicious selection of the patients most likely to benefit from this technology and provide a unified interventional oncological perspective.
Journal ArticleDOI
Electrochemotherapy: technological advancements for efficient electroporation-based treatment of internal tumors
Damijan Miklavčič,Gregor Sersa,Erik Brecelj,Julie Gehl,Declan M. Soden,Giuseppe Bianchi,Pietro Ruggieri,Carlo Riccardo Rossi,L.G. Campana,Tomaz Jarm +9 more
TL;DR: Recent technological advances in electrochemotherapy are described, which allow treatment of liver and bone metastases, soft tissue sarcomas, brain tumors, and colorectal and esophageal tumors.
Journal ArticleDOI
Radiofrequency ablation in the treatment of liver metastases from colorectal cancer
Roberto Cirocchi,Stefano Trastulli,Carlo Boselli,Alessandro Montedori,Davide Cavaliere,Amilcare Parisi,Giuseppe Noya,Iosief Abraha +7 more
TL;DR: A systematic review of the role of radiofrequency ablation (RFA) in the treatment of colorectal cancer patients with unresectable CRLMs found that it has superseded other ablative therapies, due to its low morbidity, mortality, safety and patient acceptability.
Journal ArticleDOI
Locoregional surgical and interventional therapies for advanced colorectal cancer liver metastases: expert consensus statements
Eddie K. Abdalla,Todd W. Bauer,Yun S. Chun,Michael I. D’Angelica,David A. Kooby,William R. Jarnagin +5 more
TL;DR: Expert consensus on locoregional and interventional therapies for the treatment of advanced CRLM is reported on, with particular focus on chemotherapy delivered by hepatic arterial infusion.
References
More filters
Journal ArticleDOI
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial
Bernard Nordlinger,Halfdan Sorbye,Bengt Glimelius,Bengt Glimelius,Graeme J. Poston,Peter M. Schlag,Philippe Rougier,Wolf O. Bechstein,John N. Primrose,Euan Walpole,Meg Finch-Jones,Daniel Jaeck,Darius F. Mirza,Rowan W. Parks,Laurence Collette,M. Praet,U. Bethe,Eric Van Cutsem,Werner Scheithauer,Thomas Gruenberger +19 more
TL;DR: In this article, the authors compared the combination of perioperative chemotherapy and surgery compared with surgery alone for patients with initially resectable liver metastases from colorectal cancer.
Journal ArticleDOI
Recurrence and Outcomes Following Hepatic Resection, Radiofrequency Ablation, and Combined Resection/Ablation for Colorectal Liver Metastases
Eddie K. Abdalla,Jean Nicolas Vauthey,Lee M. Ellis,Vickie Ellis,Raphael E. Pollock,Kristine Broglio,Kenneth R. Hess,Steven A. Curley +7 more
TL;DR: Hepatic resection is the treatment of choice for colorectal liver metastases and RFA alone or in combination with resection for unresectable patients does not provide survival comparable to resection, and provides survival only slightly superior to nonsurgical treatment.
Journal ArticleDOI
Local recurrence after hepatic radiofrequency coagulation: multivariate meta-analysis and review of contributing factors.
TL;DR: Radiofrequency coagulation by laparoscopy or laparotomy results in superior local control, independent of tumor size, and the short-term benefits of less invasiveness for the percutaneous route do not outweigh the longer-term higher risk of local recurrence.
Journal ArticleDOI
Systemic Treatment of Colorectal Cancer
Brian M. Wolpin,Robert J. Mayer +1 more
TL;DR: Ongoing randomized clinical trials are evaluating how best to combine currently available therapies, while smaller studies are evaluating new agents, with the goal of continued progress in prolonging life among patients with metastatic colorectal cancer and increasing cure rates among those with resectable disease.
Journal ArticleDOI
Survival after hepatic resection for metastatic colorectal cancer: trends in outcomes for 1,600 patients during two decades at a single institution.
Michael G. House,Hiromichi Ito,Mithat Gonen,Yuman Fong,Peter J. Allen,Ronald P. DeMatteo,Murray F. Brennan,Leslie H. Blumgart,William R. Jarnagin,Michael I. D’Angelica +9 more
TL;DR: Survival but not recurrence rates after hepatic resection for colorectal metastases have improved over time and might be attributable to improvements in patient selection, operative management, and chemotherapy.